These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 18971519)

  • 21. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. Chronic activation of sympathetic nervous system and systemic hypertension--stress shows the way.
    Fontes MA; Xavier CH
    J Appl Physiol (1985); 2010 Dec; 109(6):2004-5. PubMed ID: 21188815
    [No Abstract]   [Full Text] [Related]  

  • 22. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system.
    Cohn JN
    J Appl Physiol (1985); 2010 Dec; 109(6):2006-7. PubMed ID: 21188834
    [No Abstract]   [Full Text] [Related]  

  • 23. Rebuttal from Navar.
    Navar LG
    J Appl Physiol (1985); 2010 Dec; 109(6):2001-2. PubMed ID: 21148351
    [No Abstract]   [Full Text] [Related]  

  • 24. [Pharmacological and immunological approaches to inhibiting the renin-angiotensin system].
    Eliseev OM
    Biull Vsesoiuznogo Kardiol Nauchn Tsentra AMN SSSR; 1987; 10(1):105-9. PubMed ID: 3300696
    [No Abstract]   [Full Text] [Related]  

  • 25. Cross talk among substances can answer questions raised by clinical trials.
    Shimosawa T
    Hypertens Res; 2008 Sep; 31(9):1679-80. PubMed ID: 18971544
    [No Abstract]   [Full Text] [Related]  

  • 26. Inhibiting the renin-angiotensin system: why and in which patients.
    Berra K; Miller NH
    J Am Acad Nurse Pract; 2009 Jan; 21(1):66-75. PubMed ID: 19125897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. Systemic hypertension--involvement of the CNS to this complex puzzle.
    Moreira TS; Takakura AC; Antunes VR
    J Appl Physiol (1985); 2010 Dec; 109(6):2004. PubMed ID: 21188814
    [No Abstract]   [Full Text] [Related]  

  • 28. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. Dominant contributors for systemic hypertension--who leads, who follows?
    Braga VA
    J Appl Physiol (1985); 2010 Dec; 109(6):2007-8. PubMed ID: 21188840
    [No Abstract]   [Full Text] [Related]  

  • 29. Rebuttal from Esler, Lambert, and Schlaich.
    Esler M; Lambert E; Schlaich M
    J Appl Physiol (1985); 2010 Dec; 109(6):2000-1. PubMed ID: 21148350
    [No Abstract]   [Full Text] [Related]  

  • 30. [Vasodilators in the treatment of arterial hypertension].
    Gherasim L; Dorobanţu M
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1984; 36(4):289-302. PubMed ID: 6150533
    [No Abstract]   [Full Text] [Related]  

  • 31. Aliskiren, the first approved renin inhibitor: Clinical application and safety in the treatment of hypertension.
    Riccioni G; Vitulano N; D'Orazio N; Bellocci F
    Adv Ther; 2009 Jul; 26(7):700-10. PubMed ID: 19649581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Hypertension in patients with diabetes].
    Poulsen PL; Hansen KW; Gaede PH; Rossing P
    Ugeskr Laeger; 2009 Jun; 171(24):2031-4. PubMed ID: 19523370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antihypertensive pharmacogenetics.
    Nogueira JB
    Rev Port Cardiol; 2004 Dec; 23(12):1621-30. PubMed ID: 15732663
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Possible role of the sympathetic nervous system in the pathogenesis of hypertension.
    Zanchetti A
    J Hypertens Suppl; 1985 Dec; 3(4):S57-9. PubMed ID: 3868712
    [No Abstract]   [Full Text] [Related]  

  • 35. The management of the type 2 diabetic patient with hypertension - too late and too little: suggested improvements.
    Rydén L; Waeber B; Ruilope LM; Mancia G; Volpe M; Holzgreve H; Mogensen CE; Laurent S
    Blood Press; 2008; 17(5-6):250-9. PubMed ID: 19012063
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Recent knowledge in the pathophysiology, pathogenesis and hemodynamics of arterial hypertension as a base for scientifically founded diagnosis and therapy].
    Wedler B
    Z Arztl Fortbild (Jena); 1984; 78(24):1011-8. PubMed ID: 6528646
    [No Abstract]   [Full Text] [Related]  

  • 37. [Hypertensiology 2007].
    Middeke M
    Dtsch Med Wochenschr; 2007 Jun; 132(25-26):1368-70. PubMed ID: 17570082
    [No Abstract]   [Full Text] [Related]  

  • 38. Inhibition of the renin-angiotensin system and target organ protection.
    Iwanami J; Mogi M; Iwai M; Horiuchi M
    Hypertens Res; 2009 Apr; 32(4):229-37. PubMed ID: 19262496
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The sympathetic nervous system in hypertension: differing effects of drug treatment.
    Sleight P
    Eur Heart J; 1998 Jun; 19 Suppl F():F39-44. PubMed ID: 9651734
    [No Abstract]   [Full Text] [Related]  

  • 40. [Therapeutic progress in the area of arterial hypertension].
    Verniory A; Demanet JC
    Brux Med; 1974 Oct; 54(10):551-8. PubMed ID: 4373143
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.